Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating that Columvi (glofitamab) combined with GemOx doubles overall survival for people with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) compared with the standard rituximab-GemOx regimen. These new data further reinforce the therapy’s role as an off-the-shelf, fixed-duration option for patients unsuitable for stem-cell transplant.

Science Significance

The STARGLO results provide a robust confirmation of long-term durability for a CD20xCD3 bispecific antibody platform. After a median 35.1-month follow-up, overall survival reached 25.5 months vs. 12.5 months for the comparator arm, with particularly strong outcomes in patients treated after a single prior line, where more than 54% remained alive at 36 months. The data also suggest possible plateauing of survival curves, a phenomenon hinting at a potential curative impact for a population historically facing poor outcomes after relapse. Importantly, no new safety signals were identified, and cytokine release syndrome remained manageable and consistent with known profiles.

Regulatory Significance

The updated results strengthen the evidence base already supporting approvals of the Columvi–GemOx combination in over 50 countries, with its inclusion in major guidelines from ESMO, EHA, and NCCN. While the U.S. FDA has issued a Complete Response Letter for the supplemental biologics license, the persistence of strong clinical data and alignment with global regulatory bodies indicates continued momentum for future reconsideration. The follow-up findings also reinforce justification for label expansions and ongoing evaluations in first-line DLBCL and mantle cell lymphoma, widening its regulatory footprint.

Business Significance

For Roche, the three-year STARGLO dataset bolsters the company’s strategic leadership in T-cell-engaging bispecific antibodies, an increasingly competitive market segment. The therapy’s off-the-shelf convenience differentiates it from individualized cell therapies, enabling broader adoption across global cancer centers and driving commercial scalability. As DLBCL remains the most common subtype of non-Hodgkin lymphoma, the improved survival metrics may translate into significant market growth, strengthened reimbursement positioning, and reinforced investor confidence in Roche’s expanding hematology pipeline and combination-regimen strategy.

 

Patients’ Significance

For individuals with R/R DLBCL, especially those not eligible for autologous stem-cell transplant, the combination offers long-term remission potential and a meaningful extension of survival. The fixed-duration nature may reduce treatment burden, providing treatment-free intervals and faster initiation compared with more complex personalized therapies. The sustained recovery in immune parameters such as B-cell and IgM levels further supports a patient-centric benefit profile. Collectively, these outcomes provide patients and clinicians a more hopeful therapeutic pathway in a disease where relapse often occurs abruptly and aggressively.

Policy Significance

The STARGLO findings underscore the importance of broad access to innovative immunotherapies within oncology formularies and reinforce the policy need for timely reimbursement pathways for fixed-duration biologics. As global treatment guidelines increasingly recognize bispecific antibody–based regimens, health systems may need to adapt resource allocation models to support infusion-ready therapies that offer faster deployment and lower logistical complexity than autologous cell therapies. These data also highlight the policy imperative to expand diagnostic capacity and biomarker-driven care, ensuring equitable access to emerging hematologic innovations.

The three-year STARGLO follow-up marks a significant advance in lymphoma therapeutics, reinforcing the value of Columvi plus GemOx as a powerful option for patients with limited alternatives. As regulatory bodies, clinicians, and health systems assess how best to integrate these findings, the therapy stands poised to reshape treatment standards in relapsed or refractory DLBCL. With ongoing trials exploring earlier-line use and broader indications, the Columvi platform continues to elevate the scientific and clinical trajectory of immuno-oncology.

Source: F. Hoffmann-La Roche Ltd press release